- Home
- IGC vs INAB Comparison
IGC vs INAB Comparison
Compare IGC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IGC | INAB |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 22.9M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IGC | INAB |
|---|---|---|
| Price | $0.27 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 266.2K | 35.9K |
| Earning Date | 06-24-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,271,000.00 | N/A |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $15.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.12 |
| 52 Week High | $0.50 | $4.20 |
Technical Indicators
Market Signals| Indicator | IGC | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 44.20 |
| Support Level | N/A | $1.52 |
| Resistance Level | $0.32 | $1.81 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 12.18 | 23.53 |
Price Performance
Historical ComparisonAbout IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.